Cargando…

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

OBJECTIVES: To assess disability and quality of life (QOL) in treatment resistant schizophrenia (TRS) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. METHODOLOGY: Disability and QOL in forty patients with TRS (as per modified Kane’s criteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Nandakumar, Dhandapani, Ganesh, Ragul, Deb, Koushik S., Jain, Raka, Sood, Mamta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358813/
https://www.ncbi.nlm.nih.gov/pubmed/37485411
http://dx.doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_320_22
_version_ 1785075745714864128
author Nandakumar, Dhandapani
Ganesh, Ragul
Deb, Koushik S.
Jain, Raka
Sood, Mamta
author_facet Nandakumar, Dhandapani
Ganesh, Ragul
Deb, Koushik S.
Jain, Raka
Sood, Mamta
author_sort Nandakumar, Dhandapani
collection PubMed
description OBJECTIVES: To assess disability and quality of life (QOL) in treatment resistant schizophrenia (TRS) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. METHODOLOGY: Disability and QOL in forty patients with TRS (as per modified Kane’s criteria) were assessed using World Health Organization Disability Assessment Schedule 2.0 and World Health Organization Quality of Life–BREF. Scale for assessment of positive symptoms, scale for assessment of negative symptoms and Addenbrooke’s cognitive examination-III were used to assess positive, negative and cognitive symptoms. Medication adherence rating scale assessed medication adherence. RESULTS: Disability and QOL correlated significantly with medication adherence, negative and cognitive symptoms but not with positive symptoms. Subgroup analysis revealed significant difference between medication adherence (good vs poor) and cognitive (impairment vs non-impairment) groups. CONCLUSION: Negative and cognitive symptoms, and medication adherence correlated with disability and QOL.
format Online
Article
Text
id pubmed-10358813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103588132023-07-21 Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy Nandakumar, Dhandapani Ganesh, Ragul Deb, Koushik S. Jain, Raka Sood, Mamta Indian J Psychiatry Brief Research Communication OBJECTIVES: To assess disability and quality of life (QOL) in treatment resistant schizophrenia (TRS) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. METHODOLOGY: Disability and QOL in forty patients with TRS (as per modified Kane’s criteria) were assessed using World Health Organization Disability Assessment Schedule 2.0 and World Health Organization Quality of Life–BREF. Scale for assessment of positive symptoms, scale for assessment of negative symptoms and Addenbrooke’s cognitive examination-III were used to assess positive, negative and cognitive symptoms. Medication adherence rating scale assessed medication adherence. RESULTS: Disability and QOL correlated significantly with medication adherence, negative and cognitive symptoms but not with positive symptoms. Subgroup analysis revealed significant difference between medication adherence (good vs poor) and cognitive (impairment vs non-impairment) groups. CONCLUSION: Negative and cognitive symptoms, and medication adherence correlated with disability and QOL. Wolters Kluwer - Medknow 2023-06 2023-06-19 /pmc/articles/PMC10358813/ /pubmed/37485411 http://dx.doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_320_22 Text en Copyright: © 2023 Indian Journal of Psychiatry https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Brief Research Communication
Nandakumar, Dhandapani
Ganesh, Ragul
Deb, Koushik S.
Jain, Raka
Sood, Mamta
Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title_full Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title_fullStr Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title_full_unstemmed Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title_short Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
title_sort disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
topic Brief Research Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358813/
https://www.ncbi.nlm.nih.gov/pubmed/37485411
http://dx.doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_320_22
work_keys_str_mv AT nandakumardhandapani disabilityandqualityoflifeinpatientswithtreatmentresistantschizophreniaonlongtermclozapinetherapy
AT ganeshragul disabilityandqualityoflifeinpatientswithtreatmentresistantschizophreniaonlongtermclozapinetherapy
AT debkoushiks disabilityandqualityoflifeinpatientswithtreatmentresistantschizophreniaonlongtermclozapinetherapy
AT jainraka disabilityandqualityoflifeinpatientswithtreatmentresistantschizophreniaonlongtermclozapinetherapy
AT soodmamta disabilityandqualityoflifeinpatientswithtreatmentresistantschizophreniaonlongtermclozapinetherapy